ArriVent BioPharma, Inc.
AVBP
$22.86
$0.050.22%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -3.48% | -11.36% | 51.53% | -212.06% | -0.34% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -82.38% | 11.93% | 37.30% | 138.55% | 9.93% |
| Change in Net Operating Assets | 203.40% | -330.96% | 133.33% | -266.96% | 5.25% |
| Cash from Operations | 14.36% | -37.03% | 61.59% | -321.05% | 1.18% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -40.27% | -464.92% | -62.22% | 119.13% | -- |
| Cash from Investing | -40.27% | -464.92% | -62.22% | 119.13% | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -59.68% | 14.25% | 1,007.61% | 12,280.00% | -89.64% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -105.67% | 199.01% | -506.00% | -- | -- |
| Cash from Financing | -59.84% | 15.11% | 1,011.32% | 12,189.09% | -89.64% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -72,084.95% | -100.15% | 357.49% | 88.29% | -1,218.84% |